Thales SA
XMUN:CSF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Thales SA
XMUN:CSF
|
FR |
|
Relmada Therapeutics Inc
F:4E2
|
US |
|
A
|
Anglo American Platinum Ltd
XMUN:RPHA
|
ZA |
|
A
|
Accenture PLC
XMUN:CSA
|
IE |
|
K
|
Koninklijke Philips NV
DUS:PHI1
|
NL |
|
H
|
Home Depot Inc
BMV:HD
|
US |
|
H
|
Heidelberg Pharma AG
XMUN:HPHA
|
DE |
|
A
|
AZZ Inc
F:AI7
|
US |
|
Yamaha Motor Co Ltd
F:YMA
|
JP |
|
M
|
Mitsubishi Estate Co Ltd
XMUN:MES
|
JP |
|
H
|
Halliburton Co
F:HAL
|
US |
Wall St Price Targets
CSF Price Targets Summary
Thales SA
According to Wall Street analysts, the average 1-year price target for CSF is 294.23 EUR with a low forecast of 233.08 EUR and a high forecast of 407.33 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CSF's stock price target?
Price Target
294.23
EUR
According to Wall Street analysts, the average 1-year price target for CSF is 294.23 EUR with a low forecast of 233.08 EUR and a high forecast of 407.33 EUR.
What is the Revenue forecast for Thales SA?
Projected CAGR
8%
Over the last 14 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 5 years is 8%.
What is the Operating Income forecast for Thales SA?
Projected CAGR
14%
Over the last 14 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 5 years is 14%.
What is the Net Income forecast for Thales SA?
Projected CAGR
16%
Over the last 14 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 5 years is 16%.
